Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...

Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...